ストックスクリーナーアプリを入手
3.39
2.42%
0.08
アフターアワーズ：
3.37
-0.02
-0.59%
Abcellera Biologics Inc (ABCL) 最新ニュース
Sentiment Watch: What hedge funds are buying AbCellera Biologics IncEarnings Overview Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
What sparked AbCellera Biologics to soar over 9% after hours - MSN
AbCellera Biologics (ABCL) Goldman Sachs 45th Annual Global Healthcare Conference summary - Quartr
AbCellera Biologics Inc. (ABCL) - Minichart
Aug Intraday: Is AbCellera Biologics Inc affected by consumer sentiment - baoquankhu1.vn
AbCellera Biologics Eyes Integrated Biotech Shift; ABCL635 Phase II Data Due in Q3 at Forum - MarketBeat
Is AbCellera Biologics Inc a potential multi bagger2026 Sector Moves & Smart Money Movement Tracker - baoquankhu1.vn
Bear Alert: Is AbCellera Biologics Inc part of any ETF2026 Key Lessons & AI Optimized Trading Strategy Guides - baoquankhu1.vn
AbCellera at KeyBanc Forum: Strategic Advances in Biotech By Investing.com - Investing.com Canada
New CMO Appointment Strengthens AbCellera Biologics Inc. (ABCL)’s Push Into Immunology and Beyond - MSN
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Average Rating of "Hold" from Analysts - MarketBeat
AbCellera Biologics Q1 2025 Earnings Preview - MSN
AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says - MarketBeat
AbCellera at TD Cowen Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
DNB Asset Management AS Buys Shares of 656,208 AbCellera Biologics Inc. $ABCL - MarketBeat
Holdings Thermopylae Increases Stake in AbCellera Biologics Inc - GuruFocus
Thermopylae adds AbCellera (ABCL) shares in open-market buy - Stock Titan
AbCellera (ABCL) Is Up 18.8% After Pivoting To Clinical Stage And Filing Share Offering - simplywall.st
Thermopylae Holdings adds AbCellera (ABCL) shares in $3.27 open-market buy - Stock Titan
AbCellera (ABCL) CFO adds 42,600 shares in open-market stock purchase - Stock Titan
A Look At AbCellera Biologics (ABCL) Valuation After Narrower Losses And Pipeline Progress - simplywall.st
Decoding AbCellera Biologics Inc (ABCL): A Strategic SWOT Insigh - GuruFocus
Why AbCellera (ABCL) Is Up 11.5% After Narrowing Losses And Expanding ESOP Share Capacity – And What's Next - Yahoo Finance
AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M - Insider Monkey
Abcellera Warns Growing Generative AI Use Raises Cybersecurity, Privacy, and Operational Risks - TipRanks
AbCellera Biologics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
AbCellera Biologics (ABCL) Q4 Loss Narrows To US$0.03 EPS And Tests Bearish Narratives - simplywall.st
AbCellera (ABCL) Earnings Call: Liquidity, Risks, Catalysts - TipRanks
ABCL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AbCellera Reports Full Year 2025 Business Results - BioSpace
Why Axon Enterprise Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
What Sparked AbCellera Biologics To Soar Over 9% After Hours - Bitget
AbCellera Biologics Inc (ABCL) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges - GuruFocus
AbCellera Biologics Inc. (ABCL) reports Q4 loss, tops revenue estimates - MSN
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
AbCellera Biologics Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ABCL) 2026-02-24 - Seeking Alpha
AbCellera Biologics Q4 Earnings Call Highlights - MarketBeat
AbCellera Biologics Inc (NASDAQ:ABCL) Reports Narrower-Than-Expected Loss on Patent Settlement Windfall - ChartMill
AbCellera Biologics (NASDAQ:ABCL) Posts Earnings Results, Beats Estimates By $0.15 EPS - MarketBeat
Abcellera Biologics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
AbCellera (ABCL) Achieves Remarkable Revenue Growth in FY25 - GuruFocus
AbCellera Biologics Inc. SEC 10-K Report - TradingView
Abcellera Biologics earnings missed by $0.35, revenue topped estimates - Investing.com South Africa
AbCellera Biologics Q4 Earnings Report: What Investors Need to Know - Benzinga
AbCellera (NASDAQ: ABCL) 2025 results show revenue jump and strong liquidity - Stock Titan
AbCellera Biologics Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
1.82%
大文字化:
|
ボリューム (24 時間):